Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Trial Details

NCT ID
NCT05797168
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • AZD5335
  • Saruparib (AZD5305)
  • Bevacizumab
  • Carboplatin
  • AZD9574
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • La Jolla, California, United States|32.84727,-117.2742
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic re…
  • Participant must be ≥ 18 years at the time of signing the informed consent.
  • Willing to provide adequate archival and/or baseline tumor sample as applicable per module-specific criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →